Iovance Biotherapeutics
IOVA
286 hedge funds and large institutions have $944M invested in Iovance Biotherapeutics in 2026 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 122 increasing their positions, 58 reducing their positions, and 38 closing their positions.
110% more repeat investments, than reductions
Existing positions increased: 122 | Existing positions reduced: 58
68% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 38
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
32% more capital invested
Capital invested by funds: $715M → $944M (+$229M)
9% more funds holding
Funds holding: 263 → 286 (+23)
4% more call options, than puts
Call options by funds: $15.1M | Put options by funds: $14.6M
0.57% less ownership
Funds ownership: 65.89% → 65.32% (-0.57%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$29.7M |
| 2 |
D.E. Shaw & Co
New York
|
+$13.4M |
| 3 |
Millennium Management
New York
|
+$9.05M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$7.53M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$7.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
-$20.8M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$18.5M |
| 3 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$11.1M |
| 4 |
Morgan Stanley
New York
|
-$9.57M |
| 5 |
State Street
Boston,
Massachusetts
|
-$8.68M |
IOVA Hedge Fund Activity: Q1 2026 in Review
286 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2026, worth a combined $944M — up 32% from $715M a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new IOVA positions and 38 closed out — a net gain of 26 holders — while 122 added to existing stakes and 58 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $29.7M. The largest seller was Long Focus Capital Management, cutting an estimated $20.8M.
- 286 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2026, up from 263 in Q4 2025.
- Funds reported $944M of Iovance Biotherapeutics stock for Q1 2026, up 32% quarter-over-quarter.
- 64 funds opened new Iovance Biotherapeutics positions in Q1 2026 and 38 closed out, a net change of +26 holders.
- The largest Iovance Biotherapeutics buyer in Q1 2026 was Two Sigma Investments, an estimated $29.7M added.
- The largest Iovance Biotherapeutics seller in Q1 2026 was Long Focus Capital Management, an estimated $20.8M sold.
Based on aggregated 13F filings for Q1 2026.